#None #BD #Ypsomed #Neopak

Expansion of BD and Ypsomed Partnership

BD (Becton, Dickinson and Company) and Ypsomed are taking significant strides in their ongoing partnership aimed at addressing the rapidly expanding biologics market. This collaboration focuses on improving options for pharmaceutical companies and patients who require large volumes for self-injection systems.

The New Innovation: 5.5 mL BD Neopak™ XtraFlow™ Glass Prefillable Syringe

Recently, BD has announced the development of a new 5.5 mL version of its Neopak™ XtraFlow™ Glass Prefillable Syringe. This innovative design is fully compatible with Ypsomed's YpsoMate® 5.5 autoinjector platform, aimed specifically at meeting the needs of patients requiring subcutaneous self-injections of biologics. With advancements such as a shorter needle of 8 millimeters and thinner wall cannulas, the new syringe will enhance the throughput of medications, ensuring better flow rates and reduced injection times.

According to Patrick Jeukenne, the worldwide president of BD Pharmaceutical Systems, this syringe is a response to the increasing demand for convenient, patient-friendly solutions in high-dose biologics. He stated, "By combining our expertise in drug delivery and Ypsomed’s accolades in autoinjector technology, we're streamlining the self-injection process for patients dealing with complex health conditions."

Addressing Market Needs

The demand for large-volume subcutaneous injections has been on the rise, especially in sectors like oncology, autoimmune diseases, and metabolic disorders. In response to this, Ypsomed introduced the YpsoMate® 5.5 last year, designed to empower patients through an ergonomic build, intuitive two-step activation, and explicit usage feedback—factors that support patient confidence and ease of use.

BD's new syringe will complement this existing platform by maximizing flow efficiency and minimizing injection durations—essential elements as medication dosages and viscosities continue to climb steadily.

Ypsomed's Chief Business Officer, Ulrike Bauer, emphasized the importance of such partnerships, noting, "Together with our pharmaceutical partners, we are enhancing the subcutaneous delivery design space to account for high-dose therapies. These collaborations are imperative to propel the future of biopharmaceutical delivery."

A Track Record of Partnership

The relationship between BD and Ypsomed dates back years, beginning with the successful launch of the BD Neopak™ XtraFlow™ 2.25mL Glass Prefillable Syringe and the YpsoMate® 2.25 autoinjector. This duo showcased improved flow and optimized injection times across various drug viscosities, with success story lines reaching even thicker medications of up to 70cP.

The upcoming 5.5 mL model builds upon this success, aiming not only to speed up development but also downsize the risks tied to creating combination products. This step is pivotal in reducing the time-to-market for pharmaceutical health initiatives.

Future Developments

Currently, the BD Neopak™ XtraFlow™ 5.5 mL Glass Prefillable Syringe is under development and will go through extensive testing to confirm its compatibility with Ypsomed’s YpsoMate® 5.5 platform. Anticipating the timeline, syringe samples for feasibility studies are expected to be ready by mid-2026. Along with that, Ypsomed plans to extend the YpsoMate 5.5 platform while integrating the newly developed syringe.

About BD and Ypsomed

BD is a global leader in medical technology, continuously working to enhance healthcare by improving medical discoveries and care delivery solutions. With a dedicated workforce of more than 70,000 employees, the company addresses challenges within the healthcare sector to improve outcomes, efficiency, safety, and accessibility to medical services.

Ypsomed, headquartered in Burgdorf, Switzerland, is also renowned for developing self-injection systems over four decades, partnering effectively with pharmaceutical and biotech corporations to provide tailored self-care solutions. Their innovative portfolio simplifies the treatment process, thereby elevating the quality of life for patients dealing with chronic diseases.

This expanded partnership marks a significant advance in the biologics landscape, showcasing a commitment to improving patient outcomes through innovative medical solutions.